Gilead Sciences (GILD -2.2%) slips despite saying that topline results from two Phase 3 studies...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD -2.2%) slips despite saying that topline results from two Phase 3 studies of its nucleotide sofosbuvir met its endopoint among patients with chronic hepatitis C virus infection. Morgan Stanley reiterates its Overweight on the news, saying that additional Phase III data for sofosbuvir supports a "best in class" profile and a multi-billion dollar opportunity for GILD.